Search

Hutchison China MediTech Ltd ADR

Aperta

SettoreSettore sanitario

10.94 0.37

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.45

Massimo

11.12

Metriche Chiave

By Trading Economics

Entrata

978K

Vendite

135M

P/E

Media del settore

4.272

62.58

Margine di Profitto

0.722

Dipendenti

1,796

EBITDA

-14M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+35.68% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.9B

Apertura precedente

10.57

Chiusura precedente

10.94

Notizie sul Sentiment di mercato

By Acuity

100%

0%

322 / 340 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 lug 2026, 23:51 UTC

News

Cavco Industries Inc. announced its first-quarter earnings release date, contributing to positive investor sentiment. Shares are higher in after-market trading.

23 lug 2026, 23:51 UTC

News

Scholastic Corp shares fell in after-market trading following fourth-quarter results, where revenue of $476.1 million missed expectations and net income dropped to $9.4 million.

23 lug 2026, 23:51 UTC

News
Social Media

Leidos Holdings shares are lower in after-market trading amid concerns over long-term revenue growth, despite a backlog of $48.37 billion.

23 lug 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

23 lug 2026, 23:51 UTC

News

PayPal shares are lower in after-market trading as Stripe and Advent assess acquisition options, with prior offers reportedly considered insufficient.

23 lug 2026, 23:46 UTC

News

Delek US Holdings Inc declared a quarterly dividend of $0.255 per share, contributing to shares trading higher in after-market hours.

23 lug 2026, 23:46 UTC

News
Social Media

CSX Corp shares rose in after-market trading following stronger-than-expected second-quarter results, with earnings of $0.54 per share and revenue of $3.94 billion.

23 lug 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

23 lug 2026, 23:41 UTC

Event
News

GE Healthcare appointed George Newcomb as interim CFO and reported $5.30 billion in second-quarter revenue, with shares higher in after-market trading.

23 lug 2026, 23:41 UTC

News

Albertsons Companies reported revenue growth in Q1 2026, despite margin contraction. Shares are modestly higher in after-market trading since Thursday's close.

23 lug 2026, 23:41 UTC

News

Charter Communications launched a private offer to exchange notes, potentially issuing up to $1.75 billion in new notes, with shares trading higher in after-market hours.

23 lug 2026, 23:31 UTC

Social Media
Correlated Moves
News

Newmont Corporation's adjusted EPS of $2.10 missed estimates, with revenue at $6.12 billion, leading to a decline in after-market trading.

23 lug 2026, 23:31 UTC

News

Appian Corp's digital application update for community services workers supports over 210,000 and processed more than $100 million, boosting shares in after-market hours.

23 lug 2026, 23:26 UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

23 lug 2026, 23:26 UTC

News

Hims & Hers Health Inc shares are higher after an FDA advisory panel recommended easing restrictions on a popular peptide and Canaccord reiterated a Buy rating.

23 lug 2026, 23:21 UTC

News

Robert Half shares are trading lower in after-market hours following a second-quarter revenue decline to $1.336 billion and a cautious outlook for Q3.

23 lug 2026, 23:21 UTC

Social Media
News

Maxlinear Inc's shares fell in after-hours trading following second-quarter results, with net revenue of $168.8 million but diluted earnings of $0.02 per share.

23 lug 2026, 23:21 UTC

News

McKesson Corp shares fell in after-market trading amid weakness in the Health Care Distributors sector, despite strong annual revenue and earnings growth.

23 lug 2026, 23:02 UTC

ETF Constituents
News

Vanguard Large-Cap ETF gains after hours, supported by major holdings like Microsoft and Tesla, despite broader market declines from new tariffs announced by President Trump.

23 lug 2026, 23:02 UTC

ETF Constituents
Social Media
News

Invesco QQQ Trust Series I rises in after-market trading, supported by positive sentiment from Intel's projected capital expenditures exceeding $20 billion.

23 lug 2026, 23:02 UTC

Social Media
News

RingCentral's revenue of $657 million surpassed estimates, prompting a raised full-year guidance. Shares are higher in after-market trading, rebounding from an earlier session low.

23 lug 2026, 23:02 UTC

Correlated Moves
News

Ovintiv Inc reported second-quarter earnings that missed expectations, with an EPS of $1.62. Shares are lower in after-market trading following the results.

23 lug 2026, 23:02 UTC

Social Media
News

Appfolio Inc shares are lower in after-market trading following second-quarter earnings. Revenue guidance of $1.117 billion to $1.127 billion fell short of expectations.

23 lug 2026, 23:02 UTC

News

Selective Insurance Group shares fell in after-hours trading following mixed second-quarter results, despite net income of $127.1 million and revenue of $1.39 billion.

23 lug 2026, 23:02 UTC

News
Social Media

Comfort Systems USA reported strong Q2 earnings and revenue, but shares are trading lower in after-market hours, indicating a shift in market sentiment.

23 lug 2026, 23:02 UTC

Social Media
News

Amkor Technology announced a $1.5 billion partnership with NVIDIA to enhance packaging capacity, boosting shares significantly in after-market hours.

23 lug 2026, 23:02 UTC

Correlated Moves
News

ServiceNow shares are higher in after-market hours as Macquarie raised its price target to $110, reflecting positive market sentiment and sector dynamics.

23 lug 2026, 23:02 UTC

Social Media
News

Intel Corp reported second-quarter revenue of $16.1 billion, exceeding expectations. The positive outlook has driven shares higher in after-market hours.

23 lug 2026, 23:02 UTC

News

Boeing Co shares are lower in after-market trading after announcing the divestiture of its stake in HRL Laboratories, LLC, amid broader market pressures.

23 lug 2026, 23:01 UTC

News
Social Media
Event

Tenet Healthcare Corp reported second-quarter adjusted EPS of $6.12, exceeding estimates. Shares are trading higher in after-market hours following strong earnings and raised guidance.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

35.68% in crescita

Previsioni per 12 mesi

Media 14.87 USD  35.68%

Alto 17 USD

Basso 13.6 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

1

Acquista

2

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat